Company: TYRA
Filing Date: 2025-05-08
Form Type: S-3
Source: 0001193125-25-116008
Chunk: 53

Company: Tyra Biosciences, Inc.
Filing Date: 2025-05-08
Form: S-3
Chunk 53
---
 2025 excludes:

| • |     | 10,165,576 shares of common stock issuable upon the exercise of options outstanding as of March 31, 2025, at 
 a weighted average exercise price of $13.46 per share;                                                       |

| • |     | 6,381,950 shares of our common stock that are issuable upon the exercise of                           
 pre-funded warrants outstanding as of March 31, 2025, with an exercise price of $0.001 per share; and |

| • |     | 7,548,965 shares of common stock reserved for future issuance under our 2021 Incentive Award Plan and our 2021 
 Employee Stock Purchase Plan as of March 31, 2025.                                                             |

The foregoing table does not give effect to the exercise of any outstanding options. To the extent options are exercised, there may be further dilution to new investors. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital by issuing equity or convertible debt securities, your ownership will be further diluted. 12

PLAN OF DISTRIBUTION

We entered into the Sales Agreement with TD Cowen on May 8, 2025, under which we may issue and sell from time to time up to $150,000,000
of our common stock through or to TD Cowen as our sales agent or principal. Sales of shares of our common stock, if any, will be made in negotiated transactions, including block trades or block sales, or at market prices by any method that is deemed
to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act, including without limitation sales made through the Nasdaq Global Select Market or any other trading market for our common stock, or by any other
method permitted by law. If authorized by us in writing, TD Cowen may purchase shares of our common stock as principal. Sales pursuant to the Sales Agreement may also be made through an affiliate of TD Cowen.

TD Cowen will offer our common stock subject to the terms and conditions of the Sales Agreement on a daily basis or as otherwise agreed upon
by us and TD Cowen. We will designate the maximum amount of common stock to be sold through TD Cowen on a daily basis or otherwise determine such maximum amount together with TD Cowen. Subject to the terms